Technology
CDMO Leaders Unite for Turn-key Drug Production
Contract Development and Manufacturing Organizations (CDMOs), pharmaceutical supply chain, advanced therapies, strategic partnerships, end-to-end services, technology innovation, market consolidation, and competitive advantage.
Navigating the Complexities of Adding Rare Disease Products to Your Company’s Portfolio
Rare disease products, biopharmaceutical development, commercialization, market access, patient identification, payer contract strategy, value-based contracting, regulatory incentives, emerging technology.
ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing
ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###
Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology
ExpressionEdits Secures $13M in Seed Funding to Revolutionize Protein Therapies with AI-Driven Intronization Technology
ExpressionEdits, Protein therapies, AI-driven intronization technology, Seed funding, Biotechnology, Protein expression
Shimadzu Corporation Expands US Presence with Three New R&D Centers for Pharmaceutical Growth
Shimadzu Corporation, R&D centers, US expansion, pharmaceutical industry, business growth, innovation, technology.
NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns
NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)